Timothy Albertson, MD
Critical Care Medicine · Sacramento, CANPI 1184607236
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $414,625 of the $417,657 with a category attached, or 99.3%. Janssen Research & Development, LLC accounts for 98.6% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $266,550 and has fallen 100.0% since, to $18 in 2024. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $10,709 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$412K
- Portola Pharmaceuticals, LLC$3K
- Janssen Scientific Affairs, LLC$3K
- Genentech USA, Inc.$115
- Pfizer$20
- Merck$18
Across 350 payments — averaging $20,665 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5.4M
- Regeneron$716K
- Boehringer Ingelheim$301K
- Kadmon Corporation LLC$202K
- E.r. Squibb & Sons, L.L.C.$186K
- Bristol Myers Squibb$102K
- plus $338K from 12 others
What the payments were for
- Consulting fees$414,62599%
- Speaking & faculty fees$2,5001%
- Travel & lodging$1000%
- Food & beverage$3940%
- Education$180%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 27 | $411,750 |
| Portola Pharmaceuticals, LLC | 8 | $2,879 |
| Janssen Scientific Affairs, LLC | 1 | $2,875 |
| Genentech USA, Inc. | 1 | $115 |
| Pfizer | 1 | $20 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$2,750
How this compares
$417,657 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Roflumilast | 12 | $2,072 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Sacramento
- Chinh PhanSacramento$467K
- Ken YonedaSacramento$173K
- Muhammad AfzalSacramento$72K
- Cedric Franklin RutlandRiverside$3.2M
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
- Brian ShermanOxnard$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.